Global Corporate Venturing | August 5, 2019: E-commerce firm Rakuten has provided $100m in series C1 financing for Rakuten Medical, the US-based cancer-focused biotechnology developer formerly known as Aspyrian Therapeutics. Rakuten now owns 22.6% of the company, which will become an equity-method affiliate in Q3 2019.

Read the Full Article